Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.

By Pérez Núñez, Ángel | Cantero, Diana | Hernández Laín, Aurelio. Molecular cancer therapeutics, 2015 . 14(7):1548-58. , Formato Vancouver: Zahonero C, Aguilera P, Ramírez Castillejo C, Pajares M, Bolós MV, Cantero D et al. Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma. Mol Cancer Ther. 2015 Jul;14(7):1548-58.

Place Hold on Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.

A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O-6-Methylguanine-DNA Methyltransferase Promoter.

By Grávalos Castro, Cristina. Molecular cancer therapeutics, 2013 . 12(5):809-18. , Formato Vancouver: Hochhauser D, Glynne-Jones R, Potter V, Grávalos C, Doyle TJ, Pathiraja K et al. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther. 2013 May;12(5):809-18.

Place Hold on A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O-6-Methylguanine-DNA Methyltransferase Promoter.

Search for 'Provider:Molecular cancer therapeutics,'

Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.

A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O-6-Methylguanine-DNA Methyltransferase Promoter.